Patient-perceived barriers to antiretroviral adherence: associations with race

被引:45
作者
Ferguson, TF
Stewart, KE
Funkhouser, E
Tolson, J
Westfall, AO
Saag, MS
机构
[1] Univ Alabama, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA
[2] Univ Alabama, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA
[3] Univ Alabama, Ctr AIDS Res, Div Prevent Med, Birmingham, AL 35294 USA
[4] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA
[5] Univ Alabama, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA
[6] Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA
来源
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV | 2002年 / 14卷 / 05期
关键词
D O I
10.1080/0954012021000005434
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
New antiretroviral (ARV) regimens require strict adherence if optimal suppression of HIV is to be maintained. This study is a theory-based examination of racial differences in patient-perceived barriers and reported ARV adherence. Participants (N=149) completed the Patient Medication Adherence Questionnaire (PMAQ), measuring adherence and perceived barriers to adherence. Adherence was defined as a self-report of 100% adherence in the past four weeks. Odds ratios were calculated to determine the relation of reported barriers to adherence for race and gender groups, and for the sample overall. For every ten-point increase in barrier score, there was an 86% increased risk of being non-adherent (OR=1.86; 95% CI: 1.19, 2.91). Adherence was not different between racial and gender groups, nor was total barrier score. However, individual barriers were differentially endorsed across groups. Rather than relying on demographic predictors, which may be only an indirect marker of adherence, evaluations of adherence should examine the psychological and social barriers to positive adherence outcomes in individual patients. Our findings support the use of theory-based behavioural interventions that address perceived barriers to adherence and other health promotion activities.
引用
收藏
页码:607 / 617
页数:11
相关论文
共 39 条
[1]  
[Anonymous], 1974, Health Education Monograph, V2, P324
[2]  
[Anonymous], J APPL BIOBEHAV RES
[3]  
BANGSBERG DR, 1998, 5 C RETR OPP INF
[4]  
BESCH CL, 1997, 4 C RETR OPP INF, V111, P254
[5]   HIV AND AIDS AMONG ADOLESCENTS IN THE UNITED-STATES - INCREASING RISK IN THE 1990S [J].
BOWLER, S ;
SHEON, AR ;
DANGELO, LJ ;
VERMUND, SH .
JOURNAL OF ADOLESCENCE, 1992, 15 (04) :345-371
[6]  
BROERS B, 1994, ARCH INTERN MED, V154, P1121, DOI 10.1001/archinte.154.10.1121
[7]  
CATT S, 1995, AIDS CARE, V7, P229, DOI 10.1080/09540129550126731
[8]  
CORTESE L, 1993, INT C AIDS, V9, P507
[9]   HIV-1 protease inhibitors - A review for clinicians [J].
Deeks, SG ;
Smith, M ;
Holodniy, M ;
Kahn, JO .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (02) :145-153
[10]  
DEMASI R, 1999, 6 C RETR OPP INF, V85